Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397488 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00397488: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00397488 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397488, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.
Interventions
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397488
The ClinicalTrials.gov registry entry for NCT00397488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sunitinib malate is the first listed.
NCT00397488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00397488 about?
NCT00397488 is a clinical study titled "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium". RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the...
What is the current status of trial NCT00397488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2006-09. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00397488?
The interventions under investigation include: sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00397488?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.